Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

by Eclosion Team | Oct 20, 2020 | Uncategorized

Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), abiopharmaceutical company andleader inNOXtherapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA)for...

GeNeuro announces the publication in Science Advances of data establishing clear link between human endogenous retroviral proteins and psychotic disorders

by Eclosion Team | Jul 21, 2020 | Uncategorized

Geneva, Switzerland,21July2020 –08:00amCEST –GeNeuro(Euronext Paris: CH0308403085 –GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced...

GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)

by Eclosion Team | Jun 25, 2020 | Uncategorized

Geneva, Switzerland, June 25, 2020–7:30 amCEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple sclerosis...

NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors

by Eclosion Team | May 5, 2020 | Uncategorized

NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate anti-PD-1 resistance   Lyon,...

GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer

by Eclosion Team | Apr 21, 2020 | Uncategorized

Geneva, Switzerland, April 21, 2020–7:30am CEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple...